A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.

Authors

Shigenori Kadowaki

Aichi Cancer Center Hospital, Nagoya, Japan

Shigenori Kadowaki , Toshiki Masuishi , Takashi Ura , Seiichiro Mitani , Yukiya Narita , Kyoko Kato , Kazunori Honda , Hiroya Taniguchi , Masashi Ando , Kei Muro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.

First Author: Akihito Tsuji

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

First Author: Takanori Watanabe

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

First Author: Johanna C. Bendell

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).

First Author: Allyson Ocean